Looks like potetnial good news for heart failure patients
IRVINE, Calif., Dec. 14, 2017 (GLOBE NEWSWIRE) — ChromaDex Corp. (NASDAQ:CDXC), a fully integrated, science-based, nutraceutical company devoted to improving the way people age, announced important cardiac research by Dr. Mathias Mericksay and colleagues at the l’Université Paris-Sud, and Dr. Charles Brenner and colleagues at the University of Iowa, published in the journal Circulation. This research revealed that in a mouse model of heart failure, a loss of NAD levels is accompanied by activation of the nicotinamide riboside (NR) kinase pathway; administration of NIAGEN® in this model stabilizes NAD levels and leads to protective effects on cardiac function that may someday lead to a new therapeutic option for heart failure patients.
….In this new research, Drs. Mericksay, Brenner and colleagues discovered that in heart failure, activation of the NR kinase pathway, which occurs as a result of energy stress and NAD depletion is common to humans and mice. Because of activation of the NR kinase pathway, NR restores but nicotinamide fails to restore NAD levels. Measures of cardiac function are improved with oral administration of NR in this mouse model of heart failure.
Because the depression in NAD and the activation of the NR kinase pathway are common between humans and mice, the research strongly suggests that NIAGEN® may be capable of protecting against human heart failure….